|Trade names||Dothep, Prothiaden|
|AHFS/Drugs.com||International Drug Names|
|ATC code||N06AA16 (WHO)|
|Metabolism||Hepatic (via N-demethylation to active metabolite northiaden, S-oxidation and glucuronidation)|
|Biological half-life||51 hours, 14-45 hours, 54 hours (elderly)|
|Excretion||Urine (56%), faeces (15%)|
|Chemical and physical data|
|Molar mass||295.45 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Dosulepin (INN, BAN) formerly known as dothiepin (USAN), and marketed under the brand names Prothiaden, Dothep, Thaden, and Dopress, is a tricyclic antidepressant that is used in several European and South Asian countries, as well as Australia, South Africa, and New Zealand. It is not used in the United States.
Dosulepin is used for the treatment of major depressive disorder and neuropathic pain. Dosulepin is only TGA- and MHRA-approved for the treatment of major depressive disorder. There is clear evidence of the efficacy of dosulepin in psychogenic facial pain, though the drug may be needed for up to a year.
- Extrapyramidal symptoms
- Alterations to ECG patterns
- Dry mouth
- Urinary retention
- Postural hypotension
- Conduction defects
- Increased or decreased libido
- Blurred vision
- Disturbed concentration
- Peripheral neuropathy
- Paralytic ileus
- Heart block
- Myocardial infarction
- Gynecomastia (swelling of breast tissue in males)
- Testicular swelling
- Epigastric distress
- Abdominal cramps
- Parotid swellings
- Stomatitis (swelling of the mouth)
- Black tongue
- Peculiar taste sensations
- Cholestatic jaundice
- Altered liver function
- Hepatitis (swelling of the liver)
- Skin rash
- Urticaria (hives)
- Skin blisters
- Angioneurotic edema
- Weight loss
- Urinary frequency
- Weight gain
- Hyponatremia (low blood sodium)
- Movement disorders
- Dyspepsia (indigestion)
- Increased intraocular pressure
- Changes in blood sugar levels
- Thrombocytopenia (an abnormally low number of platelets in the blood. This makes one more susceptible to bleeds)
- Eosinophilia (an abnormally high amount of eosinophils in the blood)
- Agranulocytosis (a dangerously low number of white blood cells in the blood leaving one open to potentially life-threatening infections)
- Galactorrhea (lactation that is unassociated with breastfeeding and lactation)
- Epilepsy as it can lower the seizure threshold
- TCAs should not be used concomitantly or within 14 days of treatment with monoamine oxidase inhibitors due to the risk for serotonin syndrome
- Acute recovery phase following myocardial infarction as TCAs may produce conduction defects and arrhythmias
- Liver failure
- Hypersensitivity to dothiepin
Dosulepin can potentiate the effects of alcohol and at least one death has been attributed to this combination. TCAs potentiate the sedative effects of barbiturates, tranquillisers and CNS depressants. Guanethidine and other adrenergic neurone blocking drugs can have their antihypertensive effects blocked by dosulepin. Sympathomimetics may potentiate the sympathomimetic effects of dosulepin. Due to the anticholinergic and antihistamine effects of dosulepin anticholinergic and antihistamine medications may have their effects potentiated by dosulepin and hence these combinations are advised against. Dosulepin may have its postural hypotensive effects potentiated by diuretics. Anticonvulsants may have their efficacy reduced by dosulepin due to its ability to reduce the seizure threshold.
The symptoms and the treatment of an overdose are largely the same as for the other tricyclic antidepressants. Dosulepin may be particularly toxic in overdose compared to other TCAs. The onset of toxic effects is around 4–6 hours after dosulepin is ingested. In order to minimise the risk of overdose it is advised that patients only receive a limited number of tablets at a time so as to limit their risk of overdosing. It is also advised that patients are not prescribed any medications that are known to increase the risk of toxicity in those receiving dosulepin due to the potential for mixed overdoses. The medication should also be kept out of reach of children.
Mechanism of action
Dothiepin is readily absorbed from the small intestine and is extensively metabolised on first-pass through the liver into its chief active metabolite, northiaden (desmethyldosulepin). Peak plasma concentrations of between 30.4 ng/mL to 278.8 ng/mL occur within 2–3 hours of oral administration. It is distributed in breast milk and crosses the placenta and blood-brain barrier. It is highly bound to plasma proteins (84%), and has a whole-body elimination half-life of 51 hours.
- Lancaster, SG; Gonzalez, JP (July 1989). "Dothiepin: a review of its pharmcodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness". Drugs. 38 (1): 123–147. doi:10.2165/00003495-198938010-00005. PMID 2670509.
- "Dothep Dothiepin hydrochloride" (PDF). TGA eBusiness Services. Alphapharm Pty Limited. 1 November 2013. Retrieved 3 December 2013.
- Rees, JA (1981). "Clinical interpretation of pharmacokinetic data on dothiepin hydrochloride (Dosulepin, Prothiaden)". Journal of International Medical Research. 9 (2): 98–102. PMID 7227628.
- Maguire, KP; Burrows, GD; Norman, TR; Scoggins, BA (September 1981). "Metabolism and pharmacokinetics of dothiepin" (PDF). British Journal of Clinical Pharmacology. 12 (3): 405–409. doi:10.1111/j.1365-2125.1981.tb01235.x. PMC 1401810. PMID 7295471.
- Bareggi, SR; Cavallaro, R; Pirola, R; Altamura, AC (1990). "Pharmacokinetics and adverse effects of single doses of dothiepin in young and elderly subjects". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 14 (2): 163–170. doi:10.1016/0278-5846(90)90098-2. PMID 2309034.
- Ogura, C; Kishimoto, A; Mizukawa, R; Hazama, H; Honma, H; Kawahara, K (1983). "Age differences in effects on blood pressure, flicker fusion frequency, salivation and pharmacokinetics of single oral doses of dothiepin and amitriptyline". European Journal of Clinical Pharmacology. 25 (6): 811–814. doi:10.1007/BF00542525. PMID 6662179.
- Dosulepin Hydrochloride. Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. 5 December 2011. Retrieved 3 December 2013.
- Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
- Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
- C Feinmann; M Harris; R Cawley (11 February 1984). "Psychogenic facial pain: presentation and treatment.". Br Med J (Clin Res Ed). 288: 436–8. doi:10.1136/bmj.288.6415.436. PMC 1444752. PMID 6419955.
- Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
- Roth, BL; Driscol, J (12 January 2011). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 3 December 2013.